Literature DB >> 20944579

Turning the tide in lung cancer.

Malorye Allison.   

Abstract

Researchers are testing a slew of targeted therapeutic strategies in lung cancer. Signs are emerging that these therapies are gaining increasing traction in what has long been one of oncology's minefields. Malorye Allison investigates.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20944579     DOI： 10.1038/nbt1010-999

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


  10 in total

1.  Biomarker-led adaptive trial blazes a trail in breast cancer.

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2010-05       Impact factor: 54.908

2.  Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy.

Authors:  Steven M Kornblau; Mark D Minden; David B Rosen; Santosh Putta; Aileen Cohen; Todd Covey; David C Spellmeyer; Wendy J Fantl; Urte Gayko; Alessandra Cesano
Journal:  Clin Cancer Res       Date:  2010-06-04       Impact factor: 12.531

Review 3.  Functional proteomics to dissect tyrosine kinase signalling pathways in cancer.

Authors:  Walter Kolch; Andrew Pitt
Journal:  Nat Rev Cancer       Date:  2010-08-19       Impact factor: 60.716

4.  Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2.

Authors:  Xianzhong Zhang; Zhengming Xiong; Yun Wu; Weibo Cai; Jeffery R Tseng; Sanjiv S Gambhir; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2006-01       Impact factor: 10.057

Review 5.  Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the ClinicalTrials.gov website.

Authors:  Janakiraman Subramanian; Anusha R Madadi; Monica Dandona; Kristina Williams; Daniel Morgensztern; Ramaswamy Govindan
Journal:  J Thorac Oncol       Date:  2010-08       Impact factor: 15.609

6.  AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.

Authors:  Anthony Polverino; Angela Coxon; Charlie Starnes; Zobedia Diaz; Thomas DeMelfi; Ling Wang; James Bready; Juan Estrada; Russell Cattley; Stephen Kaufman; Danlin Chen; Yongmei Gan; Gondi Kumar; James Meyer; Sesha Neervannan; Gonzalo Alva; Jane Talvenheimo; Silvia Montestruque; Andrew Tasker; Vinod Patel; Robert Radinsky; Richard Kendall
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

7.  Tissue banking of diagnostic lung cancer biopsies for extraction of high quality RNA.

Authors:  Malcolm H Lawson; Doris M Rassl; Natalie M Cummings; Roslin Russell; Jaymin B Morjaria; James D Brenton; Gillian Murphy; Robert C Rintoul
Journal:  J Thorac Oncol       Date:  2010-07       Impact factor: 15.609

8.  One more fallen star--ZODIAC and its implications.

Authors:  Thomas E Stinchcombe; Ramaswamy Govindan
Journal:  Lancet Oncol       Date:  2010-07       Impact factor: 41.316

9.  Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia.

Authors:  David B Rosen; Santosh Putta; Todd Covey; Ying-Wen Huang; Garry P Nolan; Alessandra Cesano; Mark D Minden; Wendy J Fantl
Journal:  PLoS One       Date:  2010-08-25       Impact factor: 3.240

10.  Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

Authors:  William Pao; Vincent A Miller; Katerina A Politi; Gregory J Riely; Romel Somwar; Maureen F Zakowski; Mark G Kris; Harold Varmus
Journal:  PLoS Med       Date:  2005-02-22       Impact factor: 11.069
  10 in total
  1 in total

1.  Effective capture of circulating tumor cells from a transgenic mouse lung cancer model using dendrimer surfaces immobilized with anti-EGFR.

Authors:  Ja Hye Myung; Monic Roengvoraphoj; Kevin A Tam; Tian Ma; Vincent A Memoli; Ethan Dmitrovsky; Sarah J Freemantle; Seungpyo Hong
Journal:  Anal Chem       Date:  2015-09-10       Impact factor: 6.986
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.